Donepezil and Cognitive Training for Alcohol Use Disorder (AUD)

PHASE2RecruitingINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

August 8, 2022

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2027

Conditions
Alcohol Use Disorder
Interventions
COMBINATION_PRODUCT

Donepezil + Cognitive remediation therapy (CRT)

Subjects in this arm will receive (1) donepezil and (2) cognitive remediation therapy (CRT). Subjects will take 5 mg/day of oral donepezil in the evening for the first 4 weeks, then 10 mg/day of oral donepezil in the evening until week 13.

COMBINATION_PRODUCT

Donepezil + Placebo CRT

Subjects in this arm will receive (1) donepezil and (2) placebo CRT. Subjects will take 5 mg/day of oral donepezil in the evening for the first 4 weeks, then 10 mg/day of oral donepezil in the evening until week 13.

COMBINATION_PRODUCT

Placebo medication + Cognitive remediation therapy (CRT)

Subjects in this arm will receive (1) placebo medication and (2) cognitive remediation therapy (CRT). Subjects will take placebo oral medication in the evening for the first 4 weeks, then placebo oral medication in the evening until week 13.

COMBINATION_PRODUCT

Placebo medication + Placebo CRT

Subjects in this arm will receive (1) placebo medication and (2) placebo CRT. Subjects will take placebo oral medication in the evening for the first 4 weeks, then placebo oral medication in the evening until week 13.

Trial Locations (1)

06516

RECRUITING

VA Connecticut Healthcare System, West Haven

All Listed Sponsors
collaborator

Yale University

OTHER

collaborator

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

lead

VA Connecticut Healthcare System

FED

NCT05042102 - Donepezil and Cognitive Training for Alcohol Use Disorder (AUD) | Biotech Hunter | Biotech Hunter